Summary

The global Preeclampsia Therapeutics Market was valued at USD 337.02 million in 2025 and is projected to reach USD 610.77 million by 2035. The market is expected to grow at a CAGR of 6.2% during the forecast period, driven by rising cases of hypertensive disorders during pregnancy and increasing awareness regarding maternal healthcare.

Rising Prevalence of Maternal Risk Factors Driving Market Growth
One of the leading factors that are causing a higher incidence of preeclampsia internationally is the rising rates of obesity, hypertension, diabetic conditions, and delayed childbirth among women. Since the condition is one of the main causes of both maternal and fatal deaths, the increasing number of cases is fuelling the search for and availability of efficacious therapies and preventative treatments.

Segment Insights
By Drug Class:
- Antihypertensive Drugs: Widely prescribed for controlling pregnancy-related hypertension.
- Anticonvulsants: Essential for preventing seizures in severe cases.
- Corticosteroids: Support fatal lung development during premature deliveries.
- Others: Include supportive therapies for symptom management.
By Disease Severity:
- Mild: Early-stage cases requiring continuous medical monitoring.
- Severe: High-risk conditions demanding immediate therapeutic intervention.
By Route of Administration:
- Oral: Preferred for convenient long-term medication administration.
- Intravenous (IV): Enables rapid drug delivery during emergencies.
- Intramuscular (IM): Used for controlled therapeutic drug administration.
By Distribution Channel:
- Hospital Pharmacies: Major distribution channel for critical care treatments.
- Retail Pharmacies: Improve accessibility of prescribed therapeutic medications.
- Online Pharmacies: Expanding through growing digital healthcare adoption.

Due to their remarkable healthcare facilities, robust maternal-care oriented legislations, and timely embracement of advanced treatment methodologies, North America and Europe have been at the forefront of the preeclampsia therapeutics market. On the other hand, maternal-health consciousness, hospital network expansion, and prenatal-care access improvement have been the prime factors for the rapid growth of Asia-Pacific, South America, and Middle East & Africa regions.

Strong Portfolio Execution by GSK
GSK reaffirmed its long-term growth prospects by delivering a strong 2025 performance at the beginning of this year, which has been publicly disclosed in the media. Specialty medicines, a high level of research & development, and product launches in the key therapeutic areas have been the major contributors to the company's strong momentum. All these areas reflect the disciplined portfolio execution and the innovation-led strategy.

Emergence of Targeted Molecular Therapies
At present, the recent market players from the preeclampsia therapeutics segment profit strategically from the ongoing change in clinical practice from symptom management to targeted molecular therapies. A few noteworthy examples of the newer class of medicines are those based on siRNA and can silence the expression of target genes such as sFlt-1 whose overproduction is one of the hallmarks of preeclampsia, thereby leading the forefront of precision medicine aiming at the root cause of the disease instead of merely offering symptomatic relief.

Key Report Attributes
- Market Size 2025: USD 337.02 Million
- Market Size 2035: USD 610.77 Million
- CAGR (2025-2035): 6.2%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Drug Class: Antihypertensive Drugs - 5.7%, Anticonvulsants - 8.3%.
- By Disease Severity: Mild - 5.6%, Severe - 6.6%.
- By Route of Administration: Oral - 4.9%, Intravenous (IV) - 7.1%.
- By Distribution Channel: Hospital pharmacies - 5.5%, Retail pharmacies - 7.3%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ........................................... 18
2 MARKET INTRODUCTION ....................................... 20
2.1 DEFINITION ...................... 20
2.2 SCOPE OF THE STUDY ...... 20
2.3 RESEARCH OBJECTIVE ........... 20
2.4 MARKET STRUCTURE ........ 21
3 RESEARCH METHODOLOGY ................................. 22
3.1 OVERVIEW .......................... 22
3.2 DATA FLOW ........................ 24
3.2.1 DATA MINING PROCESS ...................................... 24
3.3 PURCHASED DATABASE: ........ 25
3.4 SECONDARY SOURCES: .......... 26
3.4.1 SECONDARY RESEARCH DATA FLOW: .................. 27
3.5 PRIMARY RESEARCH: ............ 28
3.5.1 PRIMARY RESEARCH DATA FLOW: ...................... 29
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ......................... 30
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ....... 30
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ........................ 31
3.6.1 REVENUE ANALYSIS APPROACH .......................... 31
3.7 DATA FORECASTING ............... 31
3.7.1 DATA FORECASTING TYPE ................................... 32
3.8 DATA MODELING .................. 33
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ................. 33
3.8.2 DATA MODELING: ..... 34
3.9 TEAMS AND ANALYST CONTRIBUTION ................................... 36
4 MARKET DYNAMICS ............................................... 38
4.1 INTRODUCTION ..................... 38
4.2 DRIVERS ............................. 39
4.2.1 RISING PREVALENCE OF RISK FACTORS ............... 39
4.2.2 INCREASED INCIDENT CASES .............................. 39
4.2.3 HIGH USE OF ANTIHYPERTENSIVES & MAGNESIUM SULFATE .......................... 40
4.2.4 INCREASING AWARENESS OF PREECLAMPSIA...... 40
4.3 RESTRAINTS ........................ 42
4.3.1 LIMITED TARGETED THERAPIES ........................... 42
4.3.2 DRUG SAFETY RESTRICTIONS IN PREGNANCY ...... 43
4.3.3 HOSPITAL BASED TREATMENT DEPENDENCY ...... 44
4.4 OPPORTUNITIES ................... 45
4.4.1 DEVELOPMENT OF NEW THERAPIES .................... 45
4.4.2 EARLY SCREENING & PREVENTIVE THERAPY ........ 45
5 MARKET FACTOR ANALYSIS ................................. 46
5.1 REGULATORY ENVIRONMENT & COMPLIANCE .......................... 46
5.2 TECHNOLOGICAL TRENDS & INNOVATION ............................... 47
5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ..................... 48
5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 48
5.4.1 NORTH AMERICA ..... 48
5.4.2 EUROPE ................... 48
5.4.3 ASIA PACIFIC ........... 49
5.4.4 REST OF THE WORLD ........................................... 49
5.4.5 REIMBURSEMENT DYNAMICS .............................. 49
5.5 MARKET ENTRY & EXIT BARRIERS .......................................... 50
5.5.1 BARRIERS TO ENTRY ........................................... 50
5.5.2 BARRIERS TO EXIT ............................................... 50
5.6 PARTNERSHIPS & COLLABORATIONS ...................................... 50
5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ............... 51
5.8 PESTLE ANALYSIS ............ 52
5.8.1 POLITICAL FACTORS ........................................... 52
5.8.2 ECONOMIC FACTORS .......................................... 52
5.8.3 SOCIAL FACTORS ..... 52
5.8.4 TECHNOLOGICAL FACTORS ................................. 53
5.8.5 LEGAL FACTORS ...... 53
5.8.6 ENVIRONMENTAL FACTORS ................................ 53
5.9 PORTER'S FIVE FORCES MODEL ........................................... 53
5.9.1 THREAT OF NEW ENTRANTS ................................ 54
5.9.2 BARGAINING POWER OF SUPPLIERS .................... 54
5.9.3 THREAT OF SUBSTITUTES ................................... 55
5.9.4 BARGAINING POWER OF BUYERS ......................... 55
5.9.5 INTENSITY OF RIVALRY ....................................... 55
5.10 PRODUCT PIPELINE ANALYSIS ............................................. 56
5.11 CASE STUDY ANALYSIS ......... 56
5.12 INVESTMENT & FUNDING SCENARIOS ................................... 57
5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ........................ 57
5.14 DISEASE OVERVIEW .............. 58
5.15 DIAGNOSIS ......................... 58
5.16 CURRENT TREATMENT ..... 59
6 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS ..... 61
6.1 OVERVIEW .......................... 61
7 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY ..................................... 64
7.1 OVERVIEW .......................... 64
8 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION ..................... 67
8.1 OVERVIEW .......................... 67
9 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL ............................ 69
9.1 OVERVIEW .......................... 69
10 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY REGION ............... 72
10.1 OVERVIEW .......................... 72
10.2 NORTH AMERICA .................. 74
10.2.1 US ........................... 78
10.2.2 CANADA .................. 80
10.3 EUROPE ............................. 82
10.3.1 GERMANY ................ 86
10.3.2 UK ........................... 88
10.3.3 FRANCE ................... 90
10.3.4 NETHERLANDS ......... 92
10.3.5 ITALY ....................... 94
10.3.6 SPAIN ...................... 96
10.3.7 REST OF EUROPE ...... 98
10.4 ASIA-PACIFIC ................... 100
10.4.1 CHINA ...................... 104
10.4.2 INDIA ....................... 106
10.4.3 JAPAN ..................... 108
10.4.4 SOUTH KOREA .......... 110
10.4.5 MALAYSIA ............... 112
10.4.6 THAILAND ................ 114
10.4.7 INDONESIA .............. 116
10.4.8 REST OF APAC ......... 118
10.5 LATIN AMERICA ................... 120
10.5.1 BRAZIL ..................... 124
10.5.2 MEXICO ................... 126
10.5.3 ARGENTINA ............. 128
10.5.4 REST OF LATIN AMERICA ..................................... 130
10.6 IDDLE EAST & AFRICA ............. 132
10.6.1 GCC COUNTRIES ...... 136
10.6.2 SOUTH AFRICA ......... 138
10.6.3 REST OF MEA ........... 140
11 COMPETITIVE LANDSCAPE ................................... 143
11.1 INTRODUCTION ..................... 143
11.2 MARKET SHARE ANALYSIS, 2025 ........................................ 143
11.3 COMPETITOR DASHBOARD ....... 144
11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES ............. 145
12 COMPANY PROFILES ............................................. 146
12.1 GLAXOSMITHKLINE ............... 146
12.1.1 COMPANY OVERVIEW .......................................... 146
12.1.2 FINANCIAL OVERVIEW ......................................... 147
12.1.3 PRODUCTS OFFERED ........................................... 147
12.1.4 SWOT ANALYSIS ...... 148
12.1.5 KEY STRATEGIES ...... 148
12.2 MERCK & CO. ..................... 149
12.2.1 COMPANY OVERVIEW .......................................... 149
12.2.2 FINANCIAL OVERVIEW ......................................... 150
12.2.3 PRODUCTS OFFERED ........................................... 150
12.2.4 SWOT ANALYSIS ...... 151
12.2.5 KEY STRATEGIES ...... 151
12.3 PFIZER INC. ........................ 152
12.3.1 COMPANY OVERVIEW .......................................... 152
12.3.2 FINANCIAL OVERVIEW ......................................... 153
12.3.3 PRODUCTS OFFERED ........................................... 153
12.3.4 SWOT ANALYSIS ...... 154
12.3.5 KEY STRATEGIES ...... 154
12.4 FRESENIUS KABI .................. 155
12.4.1 COMPANY OVERVIEW .......................................... 155
12.4.2 FINANCIAL OVERVIEW ......................................... 156
12.4.3 PRODUCTS OFFERED ........................................... 156
12.4.4 SWOT ANALYSIS ...... 157
12.4.5 KEY STRATEGIES ...... 157
12.5 BAXTER INTERNATIONAL .......... 158
12.5.1 COMPANY OVERVIEW .......................................... 158
12.5.2 FINANCIAL OVERVIEW ......................................... 159
12.5.3 PRODUCTS OFFERED ........................................... 160
12.5.4 SWOT ANALYSIS ...... 160
12.5.5 KEY STRATEGIES ...... 161
12.6 SUN PHARMACEUTICAL INDUSTRIES ..................................... 162
12.6.1 COMPANY OVERVIEW ......................................... 162
12.6.2 FINANCIAL OVERVIEW ......................................... 163
12.6.3 PRODUCTS OFFERED ........................................... 164
12.6.4 SWOT ANALYSIS ...... 164
12.6.5 KEY STRATEGIES ...... 165
12.7 HIKMA PHARMACEUTICALS ............................................... 166
12.7.1 COMPANY OVERVIEW .......................................... 166
12.7.2 FINANCIAL OVERVIEW ......................................... 167
12.7.3 PRODUCTS OFFERED ........................................... 168
12.7.4 SWOT ANALYSIS ...... 168
12.7.5 KEY STRATEGIES ...... 169
12.8 BAYER AG ........................... 170
12.8.1 COMPANY OVERVIEW .......................................... 170
12.8.2 FINANCIAL OVERVIEW ......................................... 171
12.8.3 PRODUCTS OFFERED ........................................... 172
12.8.4 SWOT ANALYSIS ...... 172
12.8.5 KEY STRATEGIES ...... 173
12.9 NOVARTIS AG ...................... 174
12.9.1 COMPANY OVERVIEW .......................................... 174
12.9.2 FINANCIAL OVERVIEW ......................................... 175
12.9.3 PRODUCTS OFFERED ........................................... 176
12.9.4 SWOT ANALYSIS ...... 176
12.9.5 KEY STRATEGIES ...... 177
12.10 ABBVIE INC........................ 178
12.10.1 COMPANY OVERVIEW .......................................... 178
12.10.2 FINANCIAL OVERVIEW ......................................... 179
12.10.3 PRODUCTS OFFERED ........................................... 179
12.10.4 SWOT ANALYSIS ...... 180
12.10.5 KEY STRATEGIES ...... 180
12.11 DATA CITATIONS .................. 181

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 35
TABLE 2 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT 48
TABLE 3 EUROPE PRICING ANALYSIS, BY PRODUCT 48
TABLE 4 ASIA PACIFIC PRICING ANALYSIS, BY PRODUCT 49
TABLE 5 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT 49
TABLE 6 PRODUCT PIPELINE 56
TABLE 7 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 62
TABLE 8 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 65
TABLE 9 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 68
TABLE 10 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 70
TABLE 11 GLOBAL PREECLAMPSIA THERAPEUTICS MARKET, BY REGION, 2019-2035 (USD MILLION) 73
TABLE 12 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 75
TABLE 13 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 76
TABLE 14 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 76
TABLE 15 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 76
TABLE 16 NORTH AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 77
TABLE 17 US PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 78
TABLE 18 US PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 78
TABLE 19 US PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 78
TABLE 20 US PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 79
TABLE 21 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 80
TABLE 22 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 80
TABLE 23 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 80
TABLE 24 CANADA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 81
TABLE 25 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 83
TABLE 26 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 84
TABLE 27 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 84
TABLE 28 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 85
TABLE 29 EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 85
TABLE 30 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 86
TABLE 31 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 86
TABLE 32 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 86
TABLE 33 GERMANY PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 87
TABLE 34 UK PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 88
TABLE 35 UK PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 88
TABLE 36 UK PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 88
TABLE 37 UK PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 89
TABLE 38 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 90
TABLE 39 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 90
TABLE 40 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 90
TABLE 41 FRANCE PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 91
TABLE 42 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 92
TABLE 43 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 92
TABLE 44 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 92
TABLE 45 NETHERLANDS PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 93
TABLE 46 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 94
TABLE 47 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 94
TABLE 48 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 94
TABLE 49 ITALY PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 95
TABLE 50 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 96
TABLE 51 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 96
TABLE 52 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 96
TABLE 53 SPAIN PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 97
TABLE 54 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 98
TABLE 55 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 98
TABLE 56 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 98
TABLE 57 REST OF EUROPE PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 99
TABLE 58 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 101
TABLE 59 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 102
TABLE 60 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 102
TABLE 61 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 103
TABLE 62 ASIA-PACIFIC PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 103
TABLE 63 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 104
TABLE 64 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 104
TABLE 65 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 104
TABLE 66 CHINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 105
TABLE 67 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 106
TABLE 68 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 106
TABLE 69 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 106
TABLE 70 INDIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 107
TABLE 71 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 108
TABLE 72 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 108
TABLE 73 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 108
TABLE 74 JAPAN PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 109
TABLE 75 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 110
TABLE 76 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 110
TABLE 77 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 110
TABLE 78 SOUTH KOREA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 111
TABLE 79 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 112
TABLE 80 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 112
TABLE 81 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 112
TABLE 82 MALAYSIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 113
TABLE 83 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 114
TABLE 84 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 114
TABLE 85 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 114
TABLE 86 THAILAND PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 115
TABLE 87 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 116
TABLE 88 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 116
TABLE 89 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 116
TABLE 90 INDONESIA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 117
TABLE 91 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 118
TABLE 92 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 118
TABLE 93 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 118
TABLE 94 REST OF APAC PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 119
TABLE 95 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 121
TABLE 96 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 122
TABLE 97 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 122
TABLE 98 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 122
TABLE 99 LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 123
TABLE 100 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 124
TABLE 101 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 124
TABLE 102 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 124
TABLE 103 BRAZIL PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 125
TABLE 104 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 126
TABLE 105 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 126
TABLE 106 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 126
TABLE 107 MEXICO PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 127
TABLE 108 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 128
TABLE 109 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 128
TABLE 110 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 128
TABLE 111 ARGENTINA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 129
TABLE 112 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 130
TABLE 113 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 130
TABLE 114 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 130
TABLE 115 REST OF LATIN AMERICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 131
TABLE 116 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 133
TABLE 117 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 134
TABLE 118 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 134
TABLE 119 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 134
TABLE 120 MIDDLE EAST & AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 135
TABLE 121 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 136
TABLE 122 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 136
TABLE 123 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 136
TABLE 124 GCC COUNTRIES PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 137
TABLE 125 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 138
TABLE 126 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 138
TABLE 127 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 138
TABLE 128 SOUTH AFRICA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 139
TABLE 129 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY DRUG CLASS, 2019-2035 (USD MILLION) 140
TABLE 130 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY DISEASE SEVERITY, 2019-2035 (USD MILLION) 140
TABLE 131 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2035 (USD MILLION) 140
TABLE 132 REST OF MEA PREECLAMPSIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2035 (USD MILLION) 141
TABLE 133 KEY DEVELOPMENT 145
TABLE 134 GLAXOSMITHKLINE: PRODUCTS OFFERED 147
TABLE 135 MERCK & CO : PRODUCT OFFERED 150
TABLE 136 PFIZER INC. : PRODUCT OFFERED 153
TABLE 137 FRESENIUS KABI . : PRODUCT OFFERED 156
TABLE 138 BAXTER INTERNATIONAL: PRODUCTS OFFERED 160
TABLE 139 SUN PHARMACEUTICAL INDUSTRIES .: PRODUCT OFFERED 164
TABLE 140 HIKMA PHARMACEUTICALS: PRODUCT OFFERED 168
TABLE 141 BAYERS AG: PRODUCT OFFERED 172
TABLE 142 NOVARTIS AG: PRODUCT OFFERED 176
TABLE 143 ABBVIE INC: PRODUCT OFFERED 179